VENLO, Netherlands, July 27, 2017 /PRNewswire/ --


        
        - Strong Q2 2017 results reaffirm QIAGEN on track to achieve full-year goals: 
        - Net sales $349.0 million (+4% actual); adjusted net sales $349.6 million (+5% actual,
          +7% CER vs. +5-6% CER guidance) 
        - EPS $0.06; adjusted EPS $0.25 ($0.25 CER), adjusted EPS excluding restructuring charge
          $0.30 ($0.30 CER vs. $0.28-0.29 CER guidance) 
        - H1 free cash flow of $91.6 million impacted by $30.8 million for restructuring 
        - Sample to Insight portfolio momentum with expansion of QuantiFERON latent TB test,
          Personalized Healthcare, NGS portfolio and QIAsymphony platform 
        - QIAGEN upgrades 2017 adjusted sales outlook after solid H1, now expects 7% CER growth;
          keeps adjusted EPS target before restructuring of $1.25-1.27 CER 

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the second quarter and first half of 2017, delivering on goals for improvements in net sales and adjusted earnings.

"QIAGEN's performance for the second quarter of 2017 further strengthens our confidence in achieving our full-year goals for strong sales growth and a double-digit increase in adjusted earnings per share, as our differentiated portfolio of Sample to Insight molecular testing solutions gains momentum," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V.

Click here for the full press release

http://corporate.qiagen.com/newsroom/press-releases/2017/2017-07-27-q2results

www.twitter.com/qiagen [http://www.twitter.com/qiagen ] 

www.facebook.com/QIAGEN [http://www.facebook.com/QIAGEN ] 

Download the QIAGEN Investor Relations App

Apple: https://itunes.apple.com/us/app/qiagen-investor-relations/id1170201291?mt=8

Android: https://play.google.com/store/apps/details?id=com.theirapp.qiagen&hl=de

        

        Contacts 
        Investor Relations: 
        John Gilardi 
        Vice President Corporate Communications and Investor Relations 
        +49-2103-29-11711 
        +1-240-686-2222 

        Dr. Sarah Fakih 
        Associate Director Investor Relations 
        +49-2103-29-11457 
        Email: ir@qiagen.com 
        ir.qiagen.com 

        Public Relations: 
        Dr. Thomas Theuringer 
        Senior Director Public Relations and Digital Communications 
        +49-2103-29-11826 
        +1-240-686-7425 
        Email: pr@qiagen.com 
        pr.qiagen.com

 

SOURCE QIAGEN N.V.